Berenberg Bank Forecasts Strong Price Appreciation for Hikma Pharmaceuticals (LON:HIK) Stock

Hikma Pharmaceuticals (LON:HIK) had its price objective increased by research analysts at Berenberg Bank from GBX 2,400 ($29.88) to GBX 2,560 ($31.87) in a report released on Wednesday,Digital Look reports. The firm presently has a “buy” rating on the stock. Berenberg Bank’s target price would indicate a potential upside of 12.28% from the stock’s previous close.

Hikma Pharmaceuticals Trading Up 1.4 %

Shares of Hikma Pharmaceuticals stock traded up GBX 32 ($0.40) during trading on Wednesday, reaching GBX 2,280 ($28.39). 1,778,026 shares of the stock were exchanged, compared to its average volume of 1,237,701. The firm has a market cap of £5.06 billion, a price-to-earnings ratio of 3,507.69, a price-to-earnings-growth ratio of 2.38 and a beta of 0.41. Hikma Pharmaceuticals has a 1 year low of GBX 1,750 ($21.79) and a 1 year high of GBX 2,290 ($28.51). The stock’s fifty day moving average is GBX 2,001.97 and its 200 day moving average is GBX 1,947.80. The company has a quick ratio of 1.27, a current ratio of 1.66 and a debt-to-equity ratio of 55.48.

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly.